FCGR3A genotype | Actual frequency of genotypes (n) | Expected frequency of genotypes (n) | Hardy-Weinberg equilibrium x2 (1 degree of freedom) | Genotyping methodology |
---|---|---|---|---|
 | Musolino, 2008 (trastuzumab) |  |  | Nested PCR-based allele-specific restriction analysis assay |
G/G (V/V) | 11 | 10.67 | 0.03 | Â |
G/T (V/F) | 26 | 26.67 | Â | Â |
T/T (F/F) | 17 | 16.67 | Â | Â |
 | Tamura, 2011 (trastuzumab) (Neoadjuvant group) |  |  | Goldengate genotyping |
G/G (V/V) | 7 | 6.67 | 0.15 | Â |
G/T (V/F) | 6 | 6.67 | Â | Â |
T/T (F/F) | 2 | 1.67 | Â | Â |
 | Tamura, 2011 (trastuzumab)(Metastatic group) |  |  | Goldengate genotyping |
G/G (V/V) | 15 | 15.78 | 0.36 | Â |
G/T (V/F) | 17 | 15.44 | Â | Â |
T/T (F/F) | 3 | 3.78 | Â | Â |
 | Hurvitz, 2011 (trastuzumab) |  |  | Nested PCR followed by Sanger sequencing (confirmed by MassARRAY) |
G/G (V/V) | 169 | 137.61 | 16.45 | Â |
G/T (V/F) | 471 | 533.78 | Â | Â |
T/T (F/F) | 549 | 517.61 | Â | Â |
 | Cartron, 2002 (rituximab) |  |  | Nested PCR followed by allele-specific restriction enzyme digestion |
G/G (V/V) | 10 | 9 | 0.34 | Â |
G/T (V/F) | 22 | 24 | Â | Â |
T/T (F/F) | 17 | 16 | Â | Â |
 | Weng, 2003 (rituximab) |  |  | Nested PCR followed by allele-specific restriction enzyme digestion. (confirmed by direct sequencing) |
G/G (V/V) | 13 | 12.52 | 0.05 | Â |
G/T (V/F) | 40 | 40.97 | Â | Â |
T/T (F/F) | 34 | 33.52 | Â | Â |
 | Persky, 2012 (rituximab) |  |  | TaqMAN SNP Assay |
G/G (V/V) | 5 | 7.04 | 1.45 | Â |
G/T (V/F) | 29 | 24.92 | Â | Â |
T/T (F/F) | 20 | 22.04 | Â | Â |
 | Kim, 2006 (rituximab) |  |  | Nested PCR followed by allele-specific restriction enzyme digestion |
G/G (V/V) | 53 | 56.64 | 2.74 | Â |
G/T (V/F) | 54 | 46.73 | Â | Â |
T/T (F/F) | 6 | 9.64 | Â | Â |
 | Dornan, 2010 (rituximab) |  |  | Allele-specific PCR with SYBR Green |
G/G (V/V) | 49 | 53.07 | 1.0 | Â |
G/T (V/F) | 202 | 192.6 | Â | Â |
T/T (F/F) | 168 | 172.7 | Â | Â |
 | Ghesquieres, 2012 (rituximab) |  |  | TaqMAN SNP Assay with specific fluorescent dye–labeled (FAM and VIC) MGB probes |
G/G (V/V) | 68 | 66.96 | 0.04 | Â |
G/T (V/F) | 215 | 217.09 | Â | Â |
T/T (F/F) | 177 | 175.96 | Â | Â |
 | Carlotti, 2007 (rituximab) |  |  | PCR with fluorescent labeled probes followed by melt curve analysis |
G/G (V/V) | 17 | 17.2 | 0.01 | Â |
G/T (V/F) | 46 | 45.59 | Â | Â |
T/T (F/F) | 30 | 30.2 | Â | Â |
 | Prochazka, 2011 (rituximab) |  |  | Nested PCR followed by allele-specific restriction enzyme digestion |
G/G (V/V) | 7 | 9.44 | 1.42 | Â |
G/T (V/F) | 43 | 38.11 | Â | Â |
T/T (F/F) | 36 | 38.44 | Â | Â |
 | Bibeau, 2009 (cetuximab) |  |  | PCR followed by multiplex allele-specific PCR (SYBR Green fluorescence) |
G/G (V/V) | 10 | 14.59 | 5.02 | Â |
G/T (V/F) | 43 | 33.82 | Â | Â |
T/T (F/F) | 15 | 19.59 | Â | Â |
 | Etienne-Grimaldi, 2012 (cetuximab) |  |  | Nested PCR followed by allele-specific restriction enzyme digestion |
G/G (V/V) | 6 | 6.71 | 0.19 | Â |
G/T (V/F) | 25 | 23.58 | Â | Â |
T/T (F/F) | 20 | 20.71 | Â | Â |
 | Zhang, 2007 (cetuximab) |  |  | Allele-specific PCR |
G/G (V/V) | 5 | 4.11 | 0.44 | Â |
G/T (V/F) | 14 | 15.77 | Â | Â |
T/T (F/F) | 16 | 15.11 | Â | Â |
 | Zhang, 2010 (cetuximab) |  |  | PCR – restriction fragment length polymorphism technique |
G/G (V/V) | 23 | 17.27 | 8.11 | Â |
G/T (V/F) | 21 | 32.47 | Â | Â |
T/T (F/F) | 21 | 15.27 | Â | Â |
 | Dahan, 2011 (cetuximab) |  |  | PCR – restriction fragment length polymorphism technique |
G/G (V/V) | 6 | 4.57 | 0.88 | Â |
G/T (V/F) | 20 | 22.86 | Â | Â |
T/T (F/F) | 30 | 28.57 | Â | Â |
 | Paez, 2010 (cetuximab) |  |  | 48.48 dynamic array (BioMark system) |
G/G (V/V) | 16 | 12.81 | 1.89 | Â |
G/T (V/F) | 41 | 47.38 | Â | Â |
T/T (F/F) | 47 | 43.81 | Â | Â |